Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

wsj.com - AdriĆ  Calatayud - Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units
Wall Street Journal –

reported higher sales for the third quarter on growth in its pharmaceuticals and diagnostics units, as the drugmaker works to secure approval for its new breast-cancer and multiple-sclerosis pills. The Swiss group said Thursday that third-quarter…

theguardian.com - Rebecca Ratcliffe - Big pharma accused of 'free-riding on nature' as global fund attracts just $7,000
Big pharma accused of 'free-riding on nature' as global fund attracts just $7,000
The Guardian –

Big pharmaceutical companies have been accused of “free-riding on nature”, after a landmark biodiversity fund that invites businesses to put some of their profits back into conservation was left virtually empty. The Cali Fund set out…

cnbc.com - Joshua Brown - Pharma's 'information arms dealer' is up nearly 80% from an April low. Josh Brown sees more gains
Pharma's 'information arms dealer' is up nearly 80% from an April low. Josh Brown sees more gains
CNBC –

(This is The Best Stocks in the Market, brought to you by Josh Brown and Sean Russo of Ritholtz Wealth Management.) Josh — On Thursdays, we use this column to highlight a single name. Sometimes it's Nvidia, sometimes it's a stock you've…

seekingalpha.com - Equity Eagle - Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine (NASDAQ:RIGL)
Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine (NASDAQ:RIGL)
Seeking Alpha –

Rigel Pharmaceuticals is evolving into a multi-product oncology platform, leveraging Big Pharma castoffs to drive growth beyond its ITP legacy. VEPPANU's U.S. launch targets a $1B ESR1-mutated breast cancer market, with early metrics excluded from…

fool.com - Reuben Gregg Brewer - 3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
The Motley Fool –

Healthcare isn't optional, which makes the pharmaceutical sector fairly resilient through the entire economic cycle. Royalty Pharma (RPRX +1.75%) has created a diversified portfolio of royalties on drugs that are approved for sale and on drugs that…

newswire.ca - Groupe LSL PHARMA INC. - LSL PHARMA GROUP INC. TO PRESENT AT THE 'PLANET MICROCAP TORONTO 2026'
LSL PHARMA GROUP INC. TO PRESENT AT THE 'PLANET MICROCAP TORONTO 2026'
CNW –

BOUCHERVILLE, QC, Oct. 22, 2026 /CNW/ -- LSL PHARMA GROUP INC. (TSXV: LSL) (the 'Corporation' or 'LSL Pharma'), a Canadian integrated pharmaceutical company, today announced it will be presenting at the Planet MicroCap Toronto 2026 powered by…

zerohedge.com - Tyler Durden - How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight
Zero Hedge –

New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine injury clinic based on a leaked statement by Jack Leslie, a senior advisor to the PR…

fool.com - RJ Fulton - Big Pharma vs. Breakthrough Biotech: Which ETF Has More Upside for Investors?
Big Pharma vs. Breakthrough Biotech: Which ETF Has More Upside for Investors?
The Motley Fool –

The Invesco Pharmaceuticals ETF (PJP -0.51%) offers a lower-volatility approach to healthcare than the Invesco Biotechnology & Genome ETF (PBE +0.35%), which prioritizes high-growth but more volatile firms specializing in genomic research and…

koreaherald.com - Kan Hyeong-woo - Zuellig Pharma expands cold chain capacity in Korea
Zuellig Pharma expands cold chain capacity in Korea
The Korea Herald –

Global healthcare logistics provider now has one of the largest cold chain storage facilities in Korea Zuellig Pharma Korea said Thursday it had expanded its cold chain facilities at its hub in Anseong, Gyeonggi Province, as demand for refrigerated…

marketbeat.com - Bender Robert & Associates Purchases New Stake in Urogen Pharma $URGN
Bender Robert & Associates Purchases New Stake in Urogen Pharma $URGN
MarketBeat –

Bender Robert & Associates purchased a new position in Urogen Pharma (NASDAQ:URGN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 34,701 shares of the company's stock…

marketbeat.com - Foster Victor Wealth Advisors LLC Acquires 33,055 Shares of Royalty Pharma PLC $RPRX
Foster Victor Wealth Advisors LLC Acquires 33,055 Shares of Royalty Pharma PLC $RPRX
MarketBeat –

Foster Victor Wealth Advisors LLC raised its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 15.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.

marketbeat.com - Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume - Should You Buy?
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume - Should You Buy?
MarketBeat –

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) saw unusually-high trading volume on Thursday. Approximately 11,255 shares were traded during trading, an increase of 65% from the previous session's…

swissinfo.ch - swissinfo.ch - Roche CEO slams Europe for failing to reward innovation
Roche CEO slams Europe for failing to reward innovation
www.swissinfo.ch –

“The US and Asia really play to win, and I feel Europe is more and more playing not to lose,” Thomas Schinecker, CEO of the Swiss drugmaker, said in an interview on Bloomberg Television. Roche will “only invest in countries in…

seekingalpha.com - High Alpha Professor - Legend Biotech Stock: CARVYKTI Makes Billions, But The Profits Are Elusive (NASDAQ:LEGN)
Legend Biotech Stock: CARVYKTI Makes Billions, But The Profits Are Elusive (NASDAQ:LEGN)
Seeking Alpha –

CARVYKTI's quarterly sales reached $710 million, but Legend's high expenses have kept recurring profitability low. Q2 results show improving operating leverage, with collaboration revenue growing faster than associated costs. I rate LEGN a cautious…

seekingalpha.com - SA Transcripts - Vimian Group AB (publ) (VIMGF) Q3 2026 Earnings Call Transcript
Vimian Group AB (publ) (VIMGF) Q3 2026 Earnings Call Transcript
Seeking Alpha –

Vimian Group AB (publ) (VIMGF) Q3 2026 Earnings Call October 22, 2026 3:00 AM EDT Alireza Tajbakhsh - Chief Executive Officer Carl Johan Boudrie - Deputy CEO, CFO & Interim Head of Specialty Pharma Adela Dashian - Jefferies LLC, Research Division…

Receive a Daily briefing on Pharma Industry News

Get Started